Cargando…

Genetic Variation in WNT9B Increases Relapse Hazard in Multiple Sclerosis

OBJECTIVE: Many multiple sclerosis (MS) genetic susceptibility variants have been identified, but understanding disease heterogeneity remains a key challenge. Relapses are a core feature of MS and a common primary outcome of clinical trials, with prevention of relapses benefiting patients immediatel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vandebergh, Marijne, Andlauer, Till F. M., Zhou, Yuan, Mallants, Klara, Held, Friederike, Aly, Lilian, Taylor, Bruce V., Hemmer, Bernhard, Dubois, Bénédicte, Goris, An
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252032/ https://www.ncbi.nlm.nih.gov/pubmed/33704824 http://dx.doi.org/10.1002/ana.26061

Ejemplares similares

Effects of Vitamin D and Body Mass Index on Disease Risk and Relapse Hazard in Multiple Sclerosis: A Mendelian Randomization Study
por: Vandebergh, Marijne, et al.
Publicado: (2022)

CHIT1 at Diagnosis Reflects Long‐Term Multiple Sclerosis Disease Activity
por: Oldoni, Emanuela, et al.
Publicado: (2020)

Body Mass Index, Interleukin-6 Signaling and Multiple Sclerosis: A Mendelian Randomization Study
por: Vandebergh, Marijne, et al.
Publicado: (2022)

Smoking and multiple sclerosis risk: a Mendelian randomization study
por: Vandebergh, Marijne, et al.
Publicado: (2020)

Quantitative MRI phenotypes capture biological heterogeneity in multiple sclerosis patients
por: Smets, Ide, et al.
Publicado: (2021)

Treatment-Induced BAFF Expression and B Cell Biology in Multiple Sclerosis
por: Smets, Ide, et al.
Publicado: (2021)

Genetic Architecture of Adaptive Immune System Identifies Key Immune Regulators
por: Lagou, Vasiliki, et al.
Publicado: (2018)

A targeted sequencing extension for transcript genotyping in single-cell transcriptomics
por: Van Horebeek, Lies, et al.
Publicado: (2023)

Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers
por: Bussas, Matthias, et al.
Publicado: (2021)

Progress in Multiple Sclerosis Genetics
por: Goris, An, et al.
Publicado: (2012)

A robust pipeline with high replication rate for detection of somatic variants in the adaptive immune system as a source of common genetic variation in autoimmune disease
por: Van Horebeek, Lies, et al.
Publicado: (2019)

From Leflunomide to Teriflunomide: Drug Development and Immuno-suppressive Oral Drugs in the Treatment of Multiple Sclerosis
por: Aly, Lilian, et al.
Publicado: (2017)

Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells
por: Smets, Ide, et al.
Publicado: (2018)

Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms
por: Heitmann, Henrik, et al.
Publicado: (2020)

Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis
por: Aly, Lilian, et al.
Publicado: (2022)

Frequent somatic mosaicism in T lymphocyte subsets in individuals with and without multiple sclerosis
por: Van Horebeek, Lies, et al.
Publicado: (2022)

The impact of disease-modifying therapies on immunoglobulin blood levels in patients with multiple sclerosis: a retrospective cross-sectional study
por: Klein, Ana, et al.
Publicado: (2023)

The Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis
por: Cirac, Ana, et al.
Publicado: (2021)

Association of the retinal vasculature, intrathecal immunity, and disability in multiple sclerosis
por: Noll, Christina, et al.
Publicado: (2022)

Seasonal variation in multiple sclerosis relapse
por: Harding, Katharine, et al.
Publicado: (2017)

Update on immunopathogenesis and immunotherapy in multiple sclerosis
por: Selter, Rebecca C, et al.
Publicado: (2013)

Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial
por: Hemmer, Bernhard, et al.
Publicado: (2023)

Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients
por: Held, Friederike, et al.
Publicado: (2021)

Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
por: Grahl, S., et al.
Publicado: (2021)

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
por: Castrop, Florian, et al.
Publicado: (2013)

New immunopathologic insights into multiple sclerosis
por: Hemmer, Bernhard, et al.
Publicado: (2003)

Effect of Seasonal Variation on Relapse Rate in Patients With Relapsing-Remitting Multiple Sclerosis in Saudi Arabia
por: Makkawi, Seraj, et al.
Publicado: (2022)

Regulation of the programmed cell death protein 1/programmed cell death ligand 1 axis in relapsing–remitting multiple sclerosis
por: Tsaktanis, Thanos, et al.
Publicado: (2023)

Remissions and Relapses in Insular Sclerosis
Publicado: (1904)

Gene Expression in Spontaneous Experimental Autoimmune Encephalomyelitis Is Linked to Human Multiple Sclerosis Risk Genes
por: Faber, Hans, et al.
Publicado: (2020)

Vaccination frequency in people newly diagnosed with multiple sclerosis
por: Darvishi, Sonia, et al.
Publicado: (2023)

Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma
por: Nobre, Liana, et al.
Publicado: (2020)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Immunologic profiles of multiple sclerosis treatments reveal shared early B cell alterations
por: Dooley, James, et al.
Publicado: (2016)

The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
por: Alroughani, Raed, et al.
Publicado: (2020)

Association of pregnancies with risk of multiple sclerosis
por: Gasperi, Christiane, et al.
Publicado: (2022)

Natural Killer Cells in Multiple Sclerosis: Entering the Stage
por: Beliën, Jarne, et al.
Publicado: (2022)

The Hazards of Major Surgery
por: Bruce, John
Publicado: (1953)

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS
por: Andlauer, Till F. M., et al.
Publicado: (2020)

White matter lesion location correlates with disability in relapsing multiple sclerosis
por: Gaetano, Laura, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0ias015hs5scv2sgimnlme8cmf